Synonyms: compound 195 [WO2021113557A1] | NX5948
Compound class:
Synthetic organic
Comment: NX-5948 (Nurix Therapeutics) is an oral BTK protein degrader. It was designed as an alternative to BTK inhibitors for potential to treat B cell malignancies, including those that carry BTK mutations which confer resistance to existing BTK inhibitors [1-2]. In contrast to NX-2127 which degrades both BTK and IKZF3, NX-5948 selectively degrades BTK. We believe NX-5948 is compound 195 in patent WO2021113557A1 [3].
|
|
References |
1. Eyre TA, Riches JC. (2023)
The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives. Cancers (Basel), 15 (9): 2596. [PMID:37174062] |
2. Robbins DW, Noviski M, Rountree R, Tan M, Brathaban N, Ingallinera T, Karr DE, Kelly A, Konst Z, Ma J et al.. (2021)
Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies. Blood, 138 (supplement): 2251. DOI: 10.1182/blood-2021-147473 |
3. Sanda AT, Kelly A. (2021)
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway. Patent number: WO2021113557A1. Assignee: Nurix Therapeutics, Inc.. Priority date: 13/12/2020. Publication date: 10/06/2021. |